OptiBiotix, a world leader in the development of human microbiome modulators, has extended its European agreement with SACCO to grant it an exclusive license to manufacture and supply its cholesterol and blood pressure reducing probiotic strain t LPLDL® to food and drink companies across the US and the rest of the world.
Sacco, a global manufacturer and supplier of probiotics and raw ingredients to the food and drink industry, will share the profits equally with Optibiotix, with a guaranteed cost of manufacture and minimum sales price. Sacco has also agreed to fund further developments including additional human studies in new territories.
This agreement provides Optibiotix with access to the US, the world’s largest probiotic market of $7.1 billion, and into the global dairy probiotic dairy market of $35.5 billion, where Sacco is particularly strong. It will also significantly reduce manufacturing cost through economies of scale which will open up new application opportunities.
LPLDL® is a revolutionary ingredient which has been proven in double blind placebo controlled trials1 to both lower cholesterol and blood pressure.
LPLDL® will be supplied as a raw ingredient by SACCO to many types of food or beverage as well as incorporated into pharmaceuticals or supplements.
Stephen O’Hara CEO of OptiBiotix commented, “We are delighted to extend our partnership with Sacco which significantly expands the scale of the commercial opportunity open to LPLDL® to new application areas and territories. We have been impressed by their ability to introduce LPLDL® to a global network of distributors and believe extending our partnership with them provides the best opportunity of developing LPLDL® into a global brand. In addition, the ability to supply competitively priced ingredients from a single manufacturer across world markets simplifies the supply chain and contract negotiations with corporate partners.”
Stephen believes this only the beginning for microbiome modulators, “LPLDL® is one of a range of approaches and products being developed by OptiBiotix which modifies the human microbiome to improve weight management, reduce cardiovascular risk, and manage diabetes. I believe we are fast approaching the next stage in the development of the microbiome in healthcare, where scientists will have the ability to precision engineer components of the microbiome to prevent, manage, and treat many of today’s chronic lifestyle diseases. OptiBiotix will continue to be at the forefront of global microbiome research and the development of new products.”
1The trials were carried out by Professor Gibson, Professor of Food Microbiology, Head of Food Microbial Sciences at University of Reading and Professor Bob Rastall, Professor of Food Biotechnology and Head of Food and Nutritional Sciences at University of Reading.
The human microbiome
The human digestive tract contains a complex and diverse ecosystem of trillions of bacteria. Recently, advances in molecular and analytical techniques (metagenomics, metabolomics) have permitted identification and quantitation of species and strains of bacteria that inhabit the gastrointestinal tract, their metabolic activity, and interactions with the human host. These studies have provided greater insight into the role of gut and their metabolites in health and disease.
NIH https://commonfund.nih.gov/hmp/index Web MD http://www.webmd.com/digestive-disorders/what-your-gut-bacteria-say-your-health#1
FOR MEDIA INFORMATION:
On behalf of Optibiotix Health plc
Simon Vane Percy
Vane Percy & Roberts
(T) +44 (0) 1737 821890
(e) simon@vanepercy.com
